Opinion|Videos|June 29, 2026
Advice for Community Oncologists on Optimizing Frontline BTKi for CLL
Author(s)Daniel Ermann, MD
Daniel Ermann, MD, shares his expert insight on proactive management of patients with chronic lymphocytic leukemia receiving BTK inhibitor (BTKi) therapy to ensure optimal treatment, particularly in older patients.
Advertisement
Episodes in this series
Daniel Ermann, MD, shares his expert insight on proactive management of patients with chronic lymphocytic leukemia receiving BTK inhibitor (BTKi) therapy to ensure optimal treatment, particularly in older patients. He says that BTKi therapy is “generally very well tolerated.” Ermann stresses the importance of counseling and monitoring older patients starting BTKi, particularly regarding their baseline cardiac comorbidity profile, as well as infection and bleeding risks.
Advertisement
Related to this article
A survey of US veterans with non-muscle invasive bladder cancer identifies barriers to treatment access, care coordination challenges, and gaps in patient education.
The perioperative regimen improved event-free and overall survival in the phase 3 VOLGA trial, offering a new option for patients with muscle-invasive bladder cancer who cannot receive or decline cisplatin.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
2
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
5